MGMT and glioblastoma: Clinical outcome was in favor ofMGMT promoter methylated tumors and low MGMT mRNAexpression: Overall, early treatment response was significantly associated withlow MGMT expression (p = 0.004), whereas the influence ofMGMT promoter methylation was less pronounced(p = 0.02) and even lost for the subgroup of patients withGBM; In the GBM subgroup 19/24 patients with low expression and 12/29 patientswith high expression exhibited tumor control or tumor shrinkage three monthsafter XRT/TMZ (p<0.01).